Quantbot Technologies LP Acquires 59,394 Shares of Boston Scientific Corporation $BSX

Key Points

• Quantbot Technologies LP has increased its stake in Boston Scientific Corporation by 74.2%, now holding 139,415 shares valued at approximately $14.06 million.
• Boston Scientific has received positive reviews from brokers, with Truist Financial raising its price target from $120 to $125 and a general consensus rating of "Buy."
• In the past 90 days, insiders at Boston Scientific have sold a total of 345,029 shares, valued at approximately $35.98 million, indicating a shift in ownership among executives.

Quantbot Technologies LP boosted its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 74.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 139,415 shares of the medical equipment provider's stock after buying an additional 59,394 shares during the quarter. Boston Scientific makes up approximately 0.4% of Quantbot Technologies LP's portfolio, making the stock its 25th biggest position. Quantbot Technologies LP's holdings in Boston Scientific were worth $14,064,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. NS Partners Ltd boosted its stake in shares of Boston Scientific by 1.6% during the first quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider's stock valued at $37,143,000 after purchasing an additional 5,704 shares during the period. Bank Pictet & Cie Europe AG boosted its stake in shares of Boston Scientific by 40.8% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock valued at $6,529,000 after purchasing an additional 21,173 shares during the period. Oppenheimer & Co. Inc. boosted its stake in shares of Boston Scientific by 18.8% during the first quarter. Oppenheimer & Co. Inc. now owns 39,523 shares of the medical equipment provider's stock valued at $3,987,000 after purchasing an additional 6,264 shares during the period. Segall Bryant & Hamill LLC purchased a new stake in shares of Boston Scientific during the first quarter valued at approximately $8,234,000. Finally, Blue Trust Inc. raised its holdings in shares of Boston Scientific by 13.0% during the first quarter. Blue Trust Inc. now owns 5,000 shares of the medical equipment provider's stock valued at $504,000 after acquiring an additional 575 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

Insider Activity

In other news, Director Yoshiaki Fujimori sold 2,901 shares of the firm's stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the transaction, the director directly owned 2,081 shares in the company, valued at $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael F. Mahoney sold 164,443 shares of the firm's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $103.69, for a total value of $17,051,094.67. Following the transaction, the chief executive officer owned 1,476,882 shares of the company's stock, valued at $153,137,894.58. The trade was a 10.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 345,029 shares of company stock valued at $35,976,603. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Up 0.7%

BSX traded up $0.7850 during trading on Friday, reaching $105.9950. The stock had a trading volume of 8,236,724 shares, compared to its average volume of 7,561,299. The stock's 50 day moving average is $103.97 and its two-hundred day moving average is $102.14. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $157.06 billion, a price-to-earnings ratio of 63.09, a P/E/G ratio of 2.55 and a beta of 0.66. Boston Scientific Corporation has a one year low of $78.53 and a one year high of $108.94.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same period last year, the company earned $0.62 earnings per share. The company's revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on BSX shares. Royal Bank Of Canada restated an "outperform" rating on shares of Boston Scientific in a report on Thursday, July 24th. Robert W. Baird upped their target price on Boston Scientific from $117.00 to $123.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Wells Fargo & Company upped their target price on Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a report on Thursday, July 24th. Wall Street Zen upgraded Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Finally, Leerink Partners started coverage on Boston Scientific in a report on Monday, June 16th. They set an "outperform" rating and a $118.00 target price for the company. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Boston Scientific currently has an average rating of "Buy" and an average target price of $117.50.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.